Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura : a retrospective observational study

Uzun, Sena LU orcid ; Frejvall, Ulf ; Karatas, Hulya ; Petersson, Per LU orcid and Sahin, Gürdal LU orcid (2026) In Frontiers in Neurology 17.
Abstract

INTRODUCTION: Migraine aura affects approximately one-third of migraine patients. In some individuals, aura remains highly disabling due to the lack of effective, targeted treatment options. This study evaluates the effectiveness and long-term management of lamotrigine (LTG) in a clinical Cohort specifically burdened by frequent or severe aura.

METHODS: A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022. The primary outcome was the proportion of patients achieving ≥50% reduction in monthly aura days (MADs) following LTG prophylaxis.

RESULTS: A total of 81 patients were included in the study. A reduction in mean MADs from 6.9 ± 7.5... (More)

INTRODUCTION: Migraine aura affects approximately one-third of migraine patients. In some individuals, aura remains highly disabling due to the lack of effective, targeted treatment options. This study evaluates the effectiveness and long-term management of lamotrigine (LTG) in a clinical Cohort specifically burdened by frequent or severe aura.

METHODS: A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022. The primary outcome was the proportion of patients achieving ≥50% reduction in monthly aura days (MADs) following LTG prophylaxis.

RESULTS: A total of 81 patients were included in the study. A reduction in mean MADs from 6.9 ± 7.5 days/month to 1.4 ± 3.7 was observed following LTG initiation, with 79.7% mean reduction (p < 0.001). The overall response rate was 85.2%. The average dose of LTG was 149.6 mg ± 70.5. Twenty-nine patients had adverse events (AE), the most common type was skin changes, and 5 dropped out of the treatment due to AEs.

DISCUSSION: The results indicate that LTG is associated with a reduction in aura frequency and is well-tolerated in patients whose migraine burden is dominated by the aura phase. LTG is a preventive option worthy of further evaluation in controlled trials.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Frontiers in Neurology
volume
17
article number
1863747
publisher
Frontiers Media S. A.
external identifiers
  • scopus:105047509437
  • pmid:42591364
ISSN
1664-2295
DOI
10.3389/fneur.2026.1863747
language
English
LU publication?
yes
additional info
Copyright © 2026 Uzun, Frejvall, Karatas, Petersson and Sahin.
id
60628d13-b9b2-45ab-ae3f-bee686bb33d1
date added to LUP
2026-09-22 11:03:13
date last changed
2026-09-23 04:00:48
@article{60628d13-b9b2-45ab-ae3f-bee686bb33d1,
  abstract     = {{<p>INTRODUCTION: Migraine aura affects approximately one-third of migraine patients. In some individuals, aura remains highly disabling due to the lack of effective, targeted treatment options. This study evaluates the effectiveness and long-term management of lamotrigine (LTG) in a clinical Cohort specifically burdened by frequent or severe aura.</p><p>METHODS: A retrospective observational study was conducted at a neurology clinic in Lund, Sweden, including 81 patients treated between 2014 and 2022. The primary outcome was the proportion of patients achieving ≥50% reduction in monthly aura days (MADs) following LTG prophylaxis.</p><p>RESULTS: A total of 81 patients were included in the study. A reduction in mean MADs from 6.9 ± 7.5 days/month to 1.4 ± 3.7 was observed following LTG initiation, with 79.7% mean reduction (p &lt; 0.001). The overall response rate was 85.2%. The average dose of LTG was 149.6 mg ± 70.5. Twenty-nine patients had adverse events (AE), the most common type was skin changes, and 5 dropped out of the treatment due to AEs.</p><p>DISCUSSION: The results indicate that LTG is associated with a reduction in aura frequency and is well-tolerated in patients whose migraine burden is dominated by the aura phase. LTG is a preventive option worthy of further evaluation in controlled trials.</p>}},
  author       = {{Uzun, Sena and Frejvall, Ulf and Karatas, Hulya and Petersson, Per and Sahin, Gürdal}},
  issn         = {{1664-2295}},
  language     = {{eng}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Neurology}},
  title        = {{Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura : a retrospective observational study}},
  url          = {{http://dx.doi.org/10.3389/fneur.2026.1863747}},
  doi          = {{10.3389/fneur.2026.1863747}},
  volume       = {{17}},
  year         = {{2026}},
}